NCT05352581 is a clinical trial of BD Veritor At-Home in Upper Respiratory Infection, sponsored by Becton, Dickinson and Company.

Who is sponsoring NCT05352581?

NCT05352581 is sponsored by Becton, Dickinson and Company.

What drugs are being tested in NCT05352581?

Interventions in NCT05352581: BD Veritor At-Home, BD Veritor Professional.

What condition does NCT05352581 study?

NCT05352581 studies Upper Respiratory Infection.

Is NCT05352581 still recruiting?

NCT05352581 is currently completed. Last updated 7 June 2023.

Last reviewed 2023-06-07 · How we verify

NCT05352581

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BD Veritor™ At-Home and BD Veritor™ Professional

Completed Last updated 7 June 2023

What this trial tests

trial testing BD Veritor At-Home in Upper Respiratory Infection in 1,146 participants. Completed in 14 April 2023.

Timeline

21 July 2022

Primary endpoint
9 March 2023

14 April 2023

Quick facts

Lead sponsor	Becton, Dickinson and Company
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,146
Start date	21 July 2022
Primary completion	9 March 2023
Estimated completion	14 April 2023
Sites	17 locations across New Zealand, United States, Australia

Drugs / interventions tested

BD Veritor At-Home
BD Veritor Professional

Conditions studied

Upper Respiratory Infection — all drugs for Upper Respiratory Infection →

Sponsor

Becton, Dickinson and Company — full company profile →

Who can join

2 and older, any sex, with Upper Respiratory Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The BD Veritor™ System is a rapid test that is testing for both COVID-19 and for Influenza This study will try to determine if the BD Veritor™ system can assist in the diagnosis of someone who has upper respiratory infection symptoms. There is both an At-Home self test and test completed by a health care professional that will be completed during this study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Upper Respiratory Infection

Currently open trials in the same condition.

NCT06876259 — Artificial Intelligence Diagnostic Decision Support to Reduce Antimicrobial Prescriptions in Young Children With Colds · NA · recruiting

Other Becton, Dickinson and Company trials

Trials by the same sponsor.

NCT06632509 — BD SiteRite(TM) 9 Ultrasound System - Clinical Study · completed
NCT06632496 — BD Prevue(TM) II Peripheral Vascular Access System With Cue(TM) Needle Tracking Technology Clinical Study · completed
NCT06604026 — Investigational Study With the BD PosiFlush™ SafeScrub on NADs · NA · recruiting
NCT06426121 — Clinical Validation of BACTEC™ Plus Aerobic/F Culture Vials Compared With Equivalent Product · completed
NCT05953363 — Prospective Clinical Evaluation of BD NRFit™ Devices and Accessories. · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05352581 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Becton, Dickinson and Company
Last refreshed: 7 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05352581.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing